| Tomudex (raltitrexed) / Pfizer, AstraZeneca |
ChiCTR-IPR-16007912: Raltitrexed based transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a single-center randomized controlled study |
|
|
| Recruiting | 4 | 200 | | TACE (raltitrexed, epirubicin and oxaliplatin) ;TACE (epirubicin and oxaliplatin) | The First Affiliated Hospital, Sun Yat-sen University; The First Affiliated Hospital, Sun Yat-sen University, Patients and health care units、Study leader | Unresectable Hepatocellular Carcinoma | | | | |
NCT03196843: Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With HNSCC. |
|
|
| Recruiting | 4 | 202 | RoW | Raltitrexed, Intensity Modulated Radiotherapy | The First Affiliated Hospital of Dalian Medical University | Head and Neck Squamous Cell Carcinoma | 08/20 | 08/23 | | |
ChiCTR1800016185: Raltitrexed-based chemotherapy as second-line treatment in advanced colorectal cancer: a prospective, multi-center, non-intervention registration study |
|
|
| Recruiting | 4 | 1000 | | raltitrexed plus Irinotecan | 81th Hospital of PLA, Dongfang Hospital Affiliated to Shanghai Tongji University; 81th Hospital of PLA, Self-raised | Colorectal Cancer | | | | |
ChiCTR1900021082: A clinical study for raltitrexed and cisplatin with concurrent intensity-modulated radiotherapy for locally advanced esophageal cancer |
|
|
| Not yet recruiting | 4 | 72 | | Tegafur + cisplatin with concurrent intensity-modulated radiotherapy ;raltitrexed and cisplatin with concurrent intensity-modulated radiotherapy | The Second Affiliated Hospital of Xi'an Jiaotong University; The Second Affiliated Hospital of Xi'an Jiaotong University, Self financing | esophageal cancer | | | | |
ChiCTR1900023114: Apatinib combined with raltitrexed approach in the treatment of patients with advanced primary liver cancer: a multi-center, single-arm, prospective, open-label clinical trial |
|
|
| Recruiting | 4 | 60 | | Apatinib 500mg orally, qd, d1-21, with 21 days as a cycle; raltitrexed , 3 mg/m2,第1天,静脉注射15 min;奥沙利铂130 mg/m2，d1, with 21 days as a cycle | Department of Oncology, Guigang City People’s Hospital, The Eighth Affiliated Hospital of Guangxi Medical University; Department of Oncology, Guigang City People’s Hospital, The Eighth Affiliated Hospital of Guangxi Medical University, self-financing | primary carcinoma of liver | | | | |
ChiCTR2000030339: A multicenter, prospective, noninterventive, and registration study for raltitrexed and S-1 in the treatment of metastatic colorectal cancer with failure of fluorouracil, oxaliplatin and irinotecan |
|
|
| Recruiting | 4 | 300 | | raltitrexed with S-1 | West China Hospital, Sichuan University; West China Hospital, Sichuan University, researchers | metastatic colorectal cancer | | | | |
CREDIT, ChiCTR2000036312: Comparison of Raltitrexed-Eluting beads vs Doxorubicin-eluting beads to Improve clinical outcome for the Treatment of?Intermediate and Late Primary Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 4 | 107 | | Nil | The Fourth Hospital of Hebei Medical University; The fourth hospital of Hebei Medical University, China Health Promotion Foundation | Hepatocellular carcinoma | | | | |
ChiCTR1800019739: A prospective, randomized, controlled clinical trial for intraoperative raltitrexed in the prevention of postoperative abdominal metastasis of colorectal cancer |
|
|
| Recruiting | 4 | 1230 | | Surgery plus intraperitoneal raltitrexed and adjuvant chemotherapy ;Surgery plus intraperitoneal normal saline and adjuvant chemotherapy | Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences, Chinese Medical Doctor Association | Advanced Colorectal Cancer | | | | |
NCT06118762: Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer |
|
|
| Recruiting | 4 | 30 | RoW | Fruquintinib, Raltitrexed | The First Affiliated Hospital of Nanchang University | Metastatic Colorectal Cancer | 10/26 | 10/26 | | |
APEC, NCT02965248: Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus no HIPEC in Locally Advanced Colorectal Cancer ( Study) |
|
|
| Recruiting | 3 | 147 | RoW | Standard adjuvant systemic chemotherapy, adjuvant oxaliplatin, 5-FU, and leucovorin calcium (mFOLFOX6), adjuvant oxaliplatin and capecitabine (CapeOx), adjuvant 5-FU and leucovorin calcium (sLV5FU2), adjuvant capecitabine (Cape), Hyperthermic intraperitoneal chemotherapy (HIPEC) with raltitrexed, Intraperitoneal raltitrexed 3 mg/m2, Hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin, I.V. leucovorin calcium 20 mg/m2, I.V. 5-FU 400 mg/m2, Intraperitoneal oxaliplatin 130 mg/m2 | Fudan University | Locally Advanced Colorectal Cancer | 11/21 | 11/23 | | |
NCT05231382: Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 3 | 426 | RoW | Raltitrexed, oxaliplatin (SALOX) treatment, Oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment | Sun Yat-sen University | Hepatocellular Carcinoma | 02/24 | 02/25 | | |
ChiCTR2000032992: A Phase III Randomized Controlled Trial of Comparison of Survival Benefit of Hepatic Arterial Infusion of Oxaliplatin plus Raltitrexed With Sorafenib for Patients With intermediate- and advanced-stage Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 3 | 130 | | Hepatic Arterial Infusion of Oxaliplatin plus Raltitrexed ;Oral sorafenib | Fujian Cancer Hospital; Fujian Cancer Hospital, Hospital funding | Hepatocellular carcinoma | | | | |
NCT05701436: Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial |
|
|
| Recruiting | 3 | 144 | RoW | Oxaliplatin, Doxorubicin, Lobaplatin, Cisplatin, Oxaliplatin, Leucovorin, fluorouracil, Lobaplatin, Raltitrexed | Zhujiang Hospital | Liver, Cancer of, Primary Resectable | 01/26 | 03/26 | | |
NCT05766605: Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial |
|
|
| Recruiting | 3 | 90 | RoW | Oxaliplatin, Doxorubicin, Lobaplatin, Cisplatin, Oxaliplatin, Leucovorin, fluorouracil, Lobaplatin, Raltitrexed | Zhujiang Hospital | Hepatocellular Carcinoma Resectable | 01/26 | 01/26 | | |
| Completed | 2 | 100 | | raltitrexed plus oxaplatin ;raltitrexed plus Irinotecan | The First Affiliated Hospital of Zhejiang University; The First Affiliated Hospital of Zhejiang University, Zhejiang Provincial Natural Science Fund (LY13H160007) | advanced colorectal cancer | | | | |
ChiCTR-IIR-17013316: A randomized, open, multicenter phase II study for efficacy and safety of Thymalfasin Alpha-1 combined with raltitrexed in patienr with advanced colorectal cancer |
|
|
| Recruiting | 2 | 60 | | Thymalfasin Alpha-1 and raltitrexed ;raltitrexed | Shanghai EAST Hospital; No 1800 Yuntai Rd, Shanghai, IIS | colorectal cancer | | | | |
ChiCTR1900020485: Phase II study for bevacizumab combined with S-1 and raltitrexed in the treatment of metastatic colorectal cancer resistant to 5-fluorouracil / oxaliplatin /irinotecan |
|
|
| Recruiting | 2 | 43 | | bevacizumab combined with S-1 and raltitrexed | West China Hospital of Sichuan University; West China Hospital, Sichuan University, researchers | metastatic colorectal cancer | | | | |
NCT04499586: A Study of Radiotherapy Combined With Raltitrexed and Irinotecan in Metastatic or Locally Recurrent Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 30 | RoW | Radiotherapy Combined With Raltitrexed and Irinotecan | Fudan University | Recurrent Colorectal Cancer | 08/20 | 12/20 | | |
ChiCTR1800018400: A Multicenter, Open, Randomized Controlled Phase II Study for the Efficacy and Safety of Raltitrexed Combined with Vinorelbine and Capecitabine Combined with Vinorelbine in the Second-line Treatment of Advanced Breast Cancer |
|
|
| Not yet recruiting | 2 | 158 | | Raltitrexed Combined with Vinorelbine ;Capecitabine Combined with Vinorelbine | The Affiliated Tumor Hospital of Guangxi Medical University; The Affiliated Tumor Hospital of Guangxi Medical University, Self-raised | Advanced Breast Cancer | | | | |
| Not yet recruiting | 2 | 66 | NA | cTACE-HAIC, OXRI | Beijing Cancer Hospital | Transarterial Chemoembolization, Hepatocellular Carcinoma | 10/21 | 10/22 | | |
NCT04241731: A Study of Cetuximab Plus Raltitrexed for Maintenance Treatment in Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 50 | RoW | Raltitrexed, Cetuximab | Jiangsu Cancer Institute & Hospital | Colorectal Cancer | 11/21 | 11/21 | | |
NCT03585530: Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus |
|
|
| Active, not recruiting | 2 | 32 | RoW | raltitrexed | Huai'an First People's Hospital | Esophagus Squamous Cell Carcinoma | 01/22 | 03/22 | | |
NCT03126071: Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 100 | RoW | Raltitrexed, Irinotecan, Oxaliplatin, Bevacizumab, Avastin | Jiangsu Cancer Institute & Hospital | Advanced Colorectal Cancer | 08/22 | 02/23 | | |
NCT04581876: The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer |
|
|
| Recruiting | 2 | 120 | RoW | raltitrexed for injection, raltitrexed, nab-paclitaxel, albumin-bound paclitaxel | Fudan University | Pancreatic Cancer, Chemotherapy Effect | 09/22 | 03/23 | | |
ChiCTR1900027159: Efficacy and safety of irinotecan combined with retitroxel regimen in salvage chemotherapy for advanced esophageal squamous cell carcinoma |
|
|
| Recruiting | 2 | 80 | | Irinotecan ;Irinotecan plus raltitrexed | The First People's Hospital of Yancheng City, Jiangsu Province; The First People's Hospital of Yancheng, The fund of applying | Advanced esophageal squamous cell cancer | | | | |
| Recruiting | 2 | 50 | RoW | Raltitrexed combined with oxaplatin, Sai Wei Jian | Second Affiliated Hospital, School of Medicine, Zhejiang University | Cholangioadenoma | 12/22 | 12/23 | | |
NCT06427005: Fruquintinib Plus S-1 and Raltitrexed (RSF) for mCRC |
|
|
| Recruiting | 2 | 66 | RoW | Fruquintinib, Elunate, S-1, Tegafur,Gimeracil and Oteracil Potassium Capsules, raltitrexed, thymidylate synthase inhibitor | West China Hospital | Fruquintinib, S-1, Raltitrexed | 06/24 | 12/24 | | |
NCT04582981: Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 136 | RoW | Fruquintinib and raltitrexed, F and R, Fruquintinib, F | Fudan University, Shanxi Province Cancer Hospital | Advanced Colorectal Carcinoma | 06/23 | 12/23 | | |
NCT05160896: SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 90 | RoW | Raltitrexed, Sai Wei Jian, Irinotecan, CPT-11, Bevacizumab, Avastin, Cetuximab, ERBITUX | Second Affiliated Hospital, School of Medicine, Zhejiang University | Advanced Metastatic Colorectal Cancer | 06/23 | 06/23 | | |
ChiCTR2100053431: Raltitrexed + Oxaliplatin (SALOX) plus Bevacizumab as the First Line Treatment in Patients with Advanced Colorectal Cancer: An Open-Label, Multicenter, Prospective Study |
|
|
| Recruiting | 2 | 90 | | Raltitrexed 3 mg/m^2 + Oxaliplatin 130 mg/m^2 + Bevacizumab 7.5 mg/kg | Medical Oncology Fujian Medical University Union Hospital; Fujian Medical University Union Hospital, Self-funded | Colorectal cancer | | | | |
NCT05435313: Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy |
|
|
| Active, not recruiting | 2 | 39 | RoW | HAIC, Fruquintinib, Tislelizumab, Raltitrexed, Oxaliplatin, Irinotecan | Fudan University | Colorectal Cancer | 01/24 | 02/24 | | |
ChiCTR2100044072: Efficacy and safety of TPF induction chemotherapy regimen containing raltitrexed in locally advanced head and neck squamous cell carcinoma |
|
|
| Recruiting | 2 | 70 | | TPF induction chemotherapy regimen | National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Hope Run Special Fund of Cancer Foundation of China | Locally advanced head and neck squamous cell carcinoma (including nasopharyngeal carcinoma) | | | | |
NCT06441019: Efficacy and Safety of HAIC in Combination With TQB2868 and Ramucirumab for Second-line Treatment of Advanced Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2 | 42 | RoW | HAIC（Oxaliplatin+ Raltitrexed）、TQB2868、Ramucirumab | Fudan University | Hepatocellular Carcinoma，Bispecific Antibodies, HAIC, Ramucirumab | 05/25 | 05/26 | | |
NCT06475287: HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2 | 42 | RoW | HAIC（Mitoxantrone+Raltitrexed）、anlotinib、TQB2450 | Fudan University | Hepatocellular Carcinoma | 07/25 | 07/26 | | |
NCT06665087: CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC |
|
|
| Not yet recruiting | 2 | 110 | NA | Ultrafractionated RT and CGA Guided systemic treatment., Ultrafractionated Radiotherapy, PD-1 antibody, Chemotherapy (Fluorouracil), Chemotherapy (Raltitrexed), Chemotherapy (Oxaliplatin), Chemotherapy (CPT-11), Targeted Therapy (anti-VEGF), Targeted Therapy (anti-EGFR) | Fudan University | Colon Cancer, Rectal Cancer | 11/27 | 11/28 | | |
NCT06652412: CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC |
|
|
| Not yet recruiting | 2 | 124 | NA | Ultrafractionated RT and CGA Guided systemic treatment., data prospectively collected, Ultrafractionated Radiotherapy, Sintilimab, Fluorouracil, Raltitrexed, Oxaliplatin, Irinotecan (CPT-11) | Fudan University | Colon Cancer, Rectal Cancer | 11/27 | 11/28 | | |
TORCH-R, NCT05628038: The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer |
|
|
| Recruiting | 2 | 93 | RoW | PD-1 antibody, Toripalimab, Capecitabine, Xeloda, 5FU, folinic acid, Oxaliplatin, Irinotecan, Raltitrexed, Cetuximab, Bevacizumab, Radiation | Fudan University | Recurrent Rectal Cancer | 12/24 | 12/25 | | |
ChiCTR2200066208: Peripheral blood ctDNA second-generation sequencing to guide RAS/BRAF wild type: A clinical study of cetuximab re-challenge in patients with metastatic colorectal cancer |
|
|
| Not yet recruiting | 2 | 27 | | Cetuximab + Sindilizumab + Raltitrexed | Anhui Cancer Hospital; Anhui Cancer Hospital, Beijing Baikouen Charity Foundation | Colorectal Cancer | | | | |
ChiCTR2300068003: Clinical study of regorafenib combined with PD-1/PD-L1 monoclonal antibody and local c-TACE in the treatment of MSS advanced colorectal cancer with liver metastasis |
|
|
| Not yet recruiting | 2 | 35 | | Interventional protocol: regorafenib and PD-1/PD-L1 treatment within 1 week before liver c-TACE, intraoperative administration: raltitrexed 4mg. | The First Affiliated Hospital of University of Science and Technology of China; The First Affiliated Hospital of University of Science and Technology of China, Self-funded | MSS type advanced colorectal cancer with liver metastasis | | | | |
ChiCTR2400091190: The Efficacy and Safety of Fruquintinib Combined with Hepatic Arterial Infusion of Leucovorin for the Treatment of Refractory Colorectal Cancer Liver Metastases: An Open-Label, Single-Arm, Single-Center, Phase II Clinical Study |
|
|
| Not yet recruiting | 2 | 30 | | Fruquintinib combined with continuous hepatic arterial infusion of raltitrexed chemotherapy. | Clinical Oncology School of Fujian Medical University,Fujian Cancer Hospital; Fujian Cancer Hospital, WU JIEPING MEDICAL FOUNDATION | Colorectal Cancer with Liver Metastasis | | | | |
ChiCTR-ONC-12002767: A Study of the Combination of Raltitrexed and Irinotecan Every Two Weeks as 2nd Line Treatment of Metastatic Colorectal Cancer |
|
|
| Completed | 1/2 | 30 | | Raltitrexed and Irinotecan | West China Hospital, Sichuan University; Level of the institution：, Nanjing Chia Tai Tianqing Pharmaceutical Co.,Ltd | Colorectal Cancer | | | | |
ChiCTR1900021702: Postoperative radiotherapy combined with raltitrexed for gastric cancer patients |
|
|
| Not yet recruiting | 1/2 | 60 | | Concurrent chemoradiation | The Second Affiliated Hospital of Soochow University; The Second Affiliated Hospital of Soochow University, None | Gastric Cancer | | | | |
NCT05426811: Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients |
|
|
| Not yet recruiting | 1/2 | 50 | NA | Regorafenib, Stivarga, Raltitrexed, Sai wei jian | China Medical University, China, The People's Hospital of Liaoning Province, Anshan Tumor Hospital, The First Affiliated Hospital of Dalian Medical University, The Second Affiliated Hospital of Dalian Medical University, Benxi Cental Hospital | Regorafenib, Raltitrexed, Colorectal Neoplasms, Third-line Treatment | 07/25 | 12/25 | | |
| Recruiting | 1 | 15 | RoW | Raltitrexed, HIPEC | Fudan University | Colorectal Cancer, Raltitrexed, HIPEC | 12/21 | 12/22 | | |
NCT05007587: Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC |
|
|
| Enrolling by invitation | 1 | 60 | RoW | Lenvatinib, LENVIMA, mFOLFOX regimen, Oxaliplatin+Leucovorin+Fluorouracil, ROX regimen, Raltitrexed+Oxaliplatin | Zhejiang Cancer Hospital, First Affiliated Hospital of Zhejiang University, First Affiliated Hospital of Wenzhou Medical University, Second Affiliated Hospital of Wenzhou Medical University, Shaoxing People's Hospital, The Third Affiliated Hospital of Wenzhou Medical University, Jinhua Central Hospital | Hepatocellular Carcinoma Stage IIIa | 06/22 | 06/23 | | |
ChiCTR-OPC-15006819: S-1 and raltitrexed for patients with metastatic colorectal cancer after failure to fluoropyrimidine, irinotecan and oxaliplatin. |
|
|
| Completed | N/A | 30 | | S-1 and raltitrexed | Department of Medical Oncology, Cancer Center, The State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University.; Department of Medical Oncology, Cancer Center, The State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University., Research Fund of West China Hospital | colorectal cancer | | | | |
ChiCTR-ONC-17010450: Adjuvant IMRT with concommitant raltitrexed chemotherapy for locally advanced gastric cancer after D0/D1 radical operation |
|
|
| Recruiting | N/A | 48 | | concurrent radiochemotherapy (IMR+Raltitrexed) | Zhongnan Hospital of Wuhan University; Zhongnan Hospital of Wuhan University, Zhongnan Hospital of Wuhan University | Gastric cancer | | | | |
ChiCTR1800016319: Clinical study of raltitrexed and cisplatin combined intensity modulated conformal radiotherapy for locally advanced esophageal cancer |
|
|
| Recruiting | N/A | 90 | | Cisplatin + raltitrexet combined with intensity modulated conformal radiation therapy ;Cisplatin+5-FU Combined with Intensity Conformal Radiation Therapy | The first hospital of China Medical University; The first hospital of China Medical University, The SCI fund of the department of radiotherapy of the first hospital of China Medical University | Esophageal cancer | | | | |
ChiCTR1900023191: A clinical study for TAE in combination with anlotinib, oxaliplatin and raltitrexed in the sequential treatment of middle or advanced primary liver cancer (PLC) |
|
|
| Recruiting | N/A | 80 | | TAE in combination with anlotinib, oxaliplatin and raltitrexed ;Symptomatic treatment | Center Hospital of Liutie; Center Hospital of Liutie, CHIA TAI TIANQING (CTTQ) Pharmaceutical Co., Ltd. | Heaptocellular Carcinoma,HCC | | | | |
ChiCTR2000030352: Multi-Center Exploratory Study of Raltitrexed for Injection Combined with Toripalimab and Anlotinib in Second-Line and Above Treatment of Advanced Esophageal and Gastric Cancer |
|
|
| Recruiting | N/A | 100 | China | Raltitrexed Combined with Toripalimab and Anlotinib ;Raltitrexed Combined with Toripalimab | Peking University International Hospital; The First Affiliated Hospital of Nanchang University ; Peking University International Hospital, Self-raised | Gastric Cancer Eesophageal Cancer | | | | |
ChiCTR1900024097: Efficacy, safety and prognosis analysis of transarterial chemoembolization with CalliSpheres drug-eluting bead loaded with raltitrexed for hepatocellular carcinoma |
|
|
| Not yet recruiting | N/A | 100 | | CalliSpheres drug-eluting bead loaded with raltitrexed | The First Affiliated Hospital of Zhengzhou University; Suzhou Hengrui Jiasheng Biomedical Technology Co., Ltd., self-financing | Hepatocellular carcinoma | | | | |
ChiCTR2000029082: Apatinib combined with continuous hepatic arterial infusion of oxaliplatin and raltitrexed in hepatocellular carcinoma with extrahepatic spread: a prospective study |
|
|
| Recruiting | N/A | 30 | | Oral apatinib combined with continuous hepatic arterial infusion of oxaliplatin and raltitrexed | Fujian Cancer Hospital; Fujian Cancer Hospital, Hospital funding | Hepatocellular Carcinoma | | | | |
ChiCTR2000029481: Safety and efficacy of radiotherapy with concurrent raltitrexed in older patients with esophageal cancer |
|
|
| Not yet recruiting | N/A | 120 | | radiotherapy+ raltitrexed ;radiotherapy | Lu'an People's Hospital; Lu'an People's Hospital, Lu'an people's Hospital | esophageal cancer | | | | |
SCHRT, NCT06408584: Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab |
|
|
| Recruiting | N/A | 25 | RoW | | Anhui Provincial Hospital | Esophageal Squamous Cell Carcinoma | 03/27 | 03/27 | | |
NCT06519578: Prospective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 1115 | RoW | hepatic artery infusion chemotherapy, HAIC | RenJi Hospital | Hepatocellular Carcinoma | 07/26 | 07/27 | | |
ChiCTR1900027801: The prospective, randomized, multicenter clinical study of the efficacy and safety of Raltitrexed combined with Irinotecan(SALIRI) compared with FOLFIRI second-line treatment in the treatment of advanced colorectal cancer |
|
|
| Recruiting | N/A | 429 | | SALIRI ;FOLFIRI | Bangwei Cao; Beijing Friendship Hospital, Capital Medical University, Beijing digestive department Collaborative Development Center | colorectal cancer | | | | |
ChiCTR2200061063: Clinical study of oxaliplatin plus raltitrexed hepatic arterial infusion chemotherapy (HAIC) combined with targeted drugs (sorafenib/lenvatinib/donafenib) in the treatment of unresectable patients with recurrent hepatocellular carcinoma after liver transplantation |
|
|
| Recruiting | N/A | 66 | | HAIC plus targeted therapy ;Only targeted therapy | The Fifth Affiliated Hospital of Sun Yat-Sen University; The Fifth Affiliated Hospital of Sun Yat-Sen University, self-raised | Hepatocellular carcinoma | | | | |
